Mesagran

Mesalazine, the active ingredient in Mesagran, is a 5‑aminosalicylic acid (5‑ASA) presented as an oral formulation for prescription use. It is employed to manage inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease, by reducing intestinal inflammation in affected patients.

GNH USA supplies Mesagran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine is used within the inflammatory bowel disease therapeutic area to control mucosal inflammation.

- Ulcerative colitis: helps induce and maintain remission by decreasing colonic inflammation. - Crohn's disease: reduces intestinal inflammation and supports symptom control in affected segments. - Maintenance therapy: sustains remission after induction therapy, limiting flare‑ups.

Mesalazine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Abdominal pain: cramping or discomfort in the gut. - Headache: transient head pain. - Rash: skin irritation or mild dermatitis.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, breathing difficulty, or hives. - Blood in stool: indicates possible colitis flare or ulceration. - Liver enzyme elevation: signs of hepatic stress. - Pancreatitis: abdominal pain with elevated enzymes. - Kidney dysfunction: reduced renal function or interstitial nephritis.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for potential complications.

- Renal function monitoring: assess baseline and periodic kidney tests. - Hepatic function monitoring: check liver enzymes before and during treatment. - Disease activity assessment: ensure active disease is present before starting. - Hypersensitivity avoidance: discontinue if allergic reaction occurs. - Pregnancy considerations: use only if benefits outweigh potential risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: may enhance anticoagulant effect, raising bleeding risk. - Methotrexate: potential additive toxicity on liver and bone marrow.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Lithium: monitor lithium levels for potential increase.